Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma

Leukemia

Volumn 17, Issue 1, 2003, Pages 196-202

  Niitsu, N ^a   Honma, Y ^b   Lijima, K ^c   Takagi, T ^d   Higashihara, M ^a   Sawada, U ^e   Okabe Kado, J ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Kanagawa Cancer Center Hospital   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell surface; nm23 H1 proteins; Non Hodgkin's lymphoma; Prognostic factor

Indexed keywords

CELL SURFACE PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE ISOLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; T CELL LYMPHOMA; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

EID: 0037265738     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402699     Document Type: Article

References (29)

1. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 200-204.
2. De La Rose A, Williams RL, Steeg PS. Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions. BioEssays 1995; 17: 53-62.
3. Okabe-Kado J, Kasukabe T, Honma Y, Hayashi M, Henzel WJ, Hozumi M. Identity of a differentiation inhibiting factor for mouse myeloid leukemia cells with nm23/nucleoside diphosphate kinase. Biochem Biophys Res Commun 1992; 182: 987-994.
4. Okabe-Kado J, Kasukabe T, Honma Y, Hayashi M, Hozumi M. Purification of a factor inhibiting differentiation from conditioned medium of nondifferentiating mouse myeloid leukemia cells. J Biol Chem 1988; 263: 10994-10999.
5. Lacombe ML, Milon L, Munier A, Mehus JG, Lambeth DO. The human nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 2000; 32: 247-258.
6. Aryee DN, Simonitsch I, Mosberger I, Kos K, Mann G, Schlogl E, Potschger U, Gadner H, Radaszkiewicz T, Kovar H. Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumor aggressiveness. Br J Cancer 1996; 74: 1693-1698.
7. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999; 94: 3541-3550.
8. Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S, Hirano M, Honma Y. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood 2001; 97: 1202-1210.
9. Niitsu N, Okabe-Kado J, Nakayama M, Wakimoto N, Sakashita A, Maseki N, Motoyoshi K, Umeda M, Honma Y. Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia. Blood 2000; 96: 1080-1086.
10. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
11. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
12. Shipp MA. A predictive model for aggressive non-Hodgkin's lymphomas. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
13. Niitsu N, Umeda M. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma. Eur J Haematol 1996; 56: 163-167.
14. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-1493.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945; 1: 80-83.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
18. Stahl, JA, Leone A, Rosengard AM, Porter L, Kin CR, Steeg PS. Identification of a second human nm23 gene, nm23-H2. Cancer Res 1991; 51: 445-449.
19. Backer JM, Mendra CE, Kovesdi I, Fairhurst JL, O'Hara B, Eddy RL, Shows TB, Methew S, Murty VV, Chaganti RS. Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes NM23-1 and NM23-2. Oncogene 1993; 8: 497-502.
20. Chandrasekharappa SC, Gross LA, King SE, Collins FS. The human NME2 gene lies within 18kb of NME1 in chromosome 17. Genes Chromosomes Cancer 1993; 6: 245-248.
21. Gilles AM, Presecan E, Vonica A, Lascu I. Nucleoside diphosphate kinase from human erythrocytes. J Biol Chem 1991; 266: 8784-8789.
22. Leone A, Seeger RC, Hong CM, Hu, YY, Arboleda MJ, Brodeur GM, Stram D, Slamon DJ, Steeg PS. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastoma. Oncogene 1993; 8: 855-865.
23. Chang C, Zhu X-X, Thoraval D, Ungar D, Rawwas J, Hora N, Strahler J, Hanash S, Radany E. nm23-H1 mutation in neuroblastoma. Nature 1994; 370: 335-336.
24. Yokoyama A, Okabe-Kado J, Wakimoto N, Kobayashi H, Sakashita A, Maseki N, Nakamaki T, Hino K, Tomoyasu S, Tsuruoka N, Motoyoshi K, Nagata N, Honma Y. Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies. Blood 1998; 91: 1845-1851.
25. Urano T, Furukawa K, Shiku H. Expression of nm23/NDP kinase proteins on the cell surface. Oncogene 1993; 8: 1371-1376.
26. Willems R, Van Bockstaele DR, Landon F, Lenjou M, Nijs G, Snoeck HW, Berneman ZN, Slegers H. Decrease in nucleoside diphosphate kinase expression during hematopoietic maturation. J Biol Chem 1993; 273: 13663-13668.
27. MacDonald NJ, de la Rosa A, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer 1995; 31: 1096-1100.
28. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
29. Aguiar RT, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, Shipp MA. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood 2000; 96: 4328-4334.